Advertisement

Topics

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Upgraded at Zacks Investment Research

14:03 EDT 4 Jul 2017 | Topix

According to Zacks, "Sucampo is focused on expanding its sole marketed product, Amitiza's label and penetrating into new markets. Moreover, the company's collaborations with firms like Takeda and Mylan for the commercialization of Amitiza is a big positive.

Original Article: Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Upgraded at Zacks Investment Research

NEXT ARTICLE

More From BioPortfolio on "Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Upgraded at Zacks Investment Research"

Advertisement
Quick Search
Advertisement
Advertisement